AngioSoma, Inc. is a publicly traded clinical stage biotechnology company focused on improving the effectiveness of current standard-of-care treatments related to endovascular interventions for peripheral artery disease (“PAD”). Liprostin™, our lead PAD treatment product candidate, successfully completed U.S. Food and Drug Administration (“FDA”) required Phase I and II clinical trials and is entering the final phase prior to approval, Phase III trials. Beyond Liprostin™, we have a robust product pipeline with existing & provisional patents, formulations, and trademarks aimed at improving the standard-of-care in treating PAD with stents, reabsorb-able stents, atherectomy catheters, and tunneling catheters.
Standard Registrar and Transfer Company
440 East 400 South, Suite 200
Salt Lake City, UT 84111
Phone: 801-571-8844 or 801-596-2150